Phospho-MBS/MYPT1 (Thr696) Antibody [K5H5]

Catalog No.: F4326

Application: Reactivity: Chicken, Human, Mouse, Rat

Lane 1: Jurkat (serum-starvation overnight), Lane 2: Jurkat (serum-starvation overnight; Calyculin A, 100 nM, 37℃, 30 min)

当該製品は品切れ状态で、ごメールアドレスを教えていただければ、在庫があると、メールで顧客様に伝えます。

代表番号: 045-509-1970|電子メール：sales@selleck.co.jp

使用情報

Dilution
WB1:1000-1:2000

Application
ELISA, IF, WB

Source
Mouse Monoclonal Antibody

Reactivity
Chicken, Human, Mouse, Rat

Storage Buffer
PBS, pH 7.2+50% Glycerol+0.05% BSA+0.01% NaN3

Storage (from the date of receipt)
-20°C (avoid freeze-thaw cycles), 2 years

Predicted MW Observed MW
115 kDa 135 kDa
^*なぜ予測分子量と実際の分子量が異なるのか？下記の原因により、実際の分子量が予測と異なる：タンパク質の翻訳後修飾（リン酸化/糖鎖付加），スプライシングバリアント，イソフォーム，相対的な電荷，ポリマー。

Datasheet & SDS

生物学的記述

Specificity
Phospho-MBS/MYPT1 (Thr696) Antibody [K5H5] detects endogenous levels of total MBS/MYPT1 protein only when it is phosphorylated at Thr696.

Clone
K5H5

Synonym(s)
MBS; MGC133042; MYPT1

Background
Phospho-MBS/MYPT1 (Thr696) marks a critical phosphorylation site on the myosin-binding subunit (MYPT1) of the myosin phosphatase complex, which pairs the PP1 catalytic subunit with MYPT1 and M20 to precisely dephosphorylate myosin light chain (MLC), thereby fine-tuning actomyosin contractility across diverse cell types. MYPT1 contains leucine-rich repeats that anchor PP1c and inhibitory phosphorylation motifs, placing Thr696 within a flexible region highly susceptible to kinase action. RhoA activation triggers ROCK to phosphorylate Thr696, prompting a conformational change that occludes the PP1c active site and sharply reduces its ability to dephosphorylate MLC, allowing phosphorylated MLC to persist and drive robust cytoskeletal tension. This mechanism feeds into the Rho/ROCK/MLC phosphatase axis, where Thr696 modification synergizes with CPI-17 phosphorylation to amplify signaling outputs, sustaining actomyosin interactions even under subsaturating calcium conditions. The result cascades into enhanced stress fiber assembly, focal adhesion reinforcement, and dynamic cell shape changes essential for migration, cytokinesis, and tissue morphogenesis in skeletal muscle and non-muscle cells. In skeletal muscle fibers, this phosphorylation modulates force generation and sarcomere organization during contraction-relaxation cycles, influencing motility and repair processes without relying on vascular-specific tone. Such dysregulation, often from excessive ROCK activity, contributes to fibrotic stiffening and impaired regeneration in musculoskeletal disorders.

Background

Phospho-MBS/MYPT1 (Thr696) marks a critical phosphorylation site on the myosin-binding subunit (MYPT1) of the myosin phosphatase complex, which pairs the PP1 catalytic subunit with MYPT1 and M20 to precisely dephosphorylate myosin light chain (MLC), thereby fine-tuning actomyosin contractility across diverse cell types. MYPT1 contains leucine-rich repeats that anchor PP1c and inhibitory phosphorylation motifs, placing Thr696 within a flexible region highly susceptible to kinase action. RhoA activation triggers ROCK to phosphorylate Thr696, prompting a conformational change that occludes the PP1c active site and sharply reduces its ability to dephosphorylate MLC, allowing phosphorylated MLC to persist and drive robust cytoskeletal tension. This mechanism feeds into the Rho/ROCK/MLC phosphatase axis, where Thr696 modification synergizes with CPI-17 phosphorylation to amplify signaling outputs, sustaining actomyosin interactions even under subsaturating calcium conditions. The result cascades into enhanced stress fiber assembly, focal adhesion reinforcement, and dynamic cell shape changes essential for migration, cytokinesis, and tissue morphogenesis in skeletal muscle and non-muscle cells. In skeletal muscle fibers, this phosphorylation modulates force generation and sarcomere organization during contraction-relaxation cycles, influencing motility and repair processes without relying on vascular-specific tone. Such dysregulation, often from excessive ROCK activity, contributes to fibrotic stiffening and impaired regeneration in musculoskeletal disorders.

References
[1] Seko T, et al. Circ Res. 2003 Mar 7;92(4):411-8. [2] Khasnis M, et al. Biochemistry. 2014 Apr 29;53(16):2701-9.

PVDFメンブレン孔径参考表

Protein Size (kDa)	PVDF Transfer Membrane Pore Size (μm)
< 10	0.22
10-20	0.22
20-30	0.45
30-45	0.45
45-70	0.45
80-100	0.45
100-140	0.45
> 140	0.45

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

* 必須

* 大学・企業名 大学・企業名を記入してください

* 名前 名前を記入してください

* 電子メール 電子メール・アドレスを記入してください 有効なメールアドレスを入力してください

電話番号

* 内容 お問い合わせ内容をご入力ください

Protein Size (kDa)	Separating Gel Percentage
4-40	20%
12-45	15%
10-70	12.5%
15-100	10%
25-100	8%
60-210	5%